RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Kaleido Biosciences - Stock

Kaleido Biosciences ROA 2024

Kaleido Biosciences ROA

-1.8

Ticker

KLDO

ISIN

US4833471000

WKN

A2PELT

In 2024, Kaleido Biosciences's return on assets (ROA) was -1.8, a 0% increase from the 0 ROA in the previous year.

Kaleido Biosciences Aktienanalyse

What does Kaleido Biosciences do?

Kaleido Biosciences Inc is a biopharmaceutical company specializing in the discovery and development of novel therapeutics for a variety of metabolic and immune disorders. The company, based in Lexington, Massachusetts, was founded in 2015 by David Berry, Michael Fischbach, Geoff von Maltzahn, and Noubar Afeyan. The founders brought together their expertise from various fields to develop a new class of drugs based on the manipulation of the microbial ecosystem in the human gut. The company has developed an innovative business model based on the Microbiome Metabolic Therapies (MMT) platform. This platform utilizes naturally occurring, non-pathogenic microorganisms to modulate specific metabolic pathways in the human body. By manipulating the microbiome, scientists at Kaleido Biosciences can influence specific disease states and develop new therapies for metabolic and immune system disorders. One of the areas of focus for the company is the treatment of various metabolic disorders, with a particular emphasis on regulating carbohydrate metabolism. Kaleido Biosciences uses the MMT platform to modify certain bacteria in the gut. The goal is to shift the balance of the gut flora in a way that promotes or suppresses specific metabolic reactions in the body. Another important area of focus is immunotherapy. The aim is to selectively influence the body's immune system to treat various disease states. Kaleido Biosciences is working on strategies to activate bacteria in the gut and trigger specific immune responses. In recent years, the company has developed several promising products and is currently in the clinical trial phase. One product is an MMT candidate for the treatment of celiac disease, an autoimmune disorder related to gluten digestion. Another product is an MMT candidate for the treatment of hyperammonemia in patients with ornithine transcarbamylase deficiency. Kaleido Biosciences also collaborates closely with various companies and partners to further develop its technology platform and identify new products. In 2018, the company entered into a strategic collaboration agreement with Pfizer to identify and develop a range of MMT candidates for the treatment of metabolic and immune disorders. Overall, Kaleido Biosciences Inc has made remarkable progress in a short period of time and developed an innovative technology platform for the development of new therapeutics for complex disease states. The company has quickly established a solid value creation community of investors, partners, and customers. With continued research efforts, partnership endeavors, and a customer-oriented approach, the future looks bright for Kaleido Biosciences. Kaleido Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Kaleido Biosciences's Return on Assets (ROA)

Kaleido Biosciences's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Kaleido Biosciences's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Kaleido Biosciences's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Kaleido Biosciences’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Kaleido Biosciences Stock

What is the Return on Assets (ROA) of Kaleido Biosciences this year?

The Return on Assets (ROA) of Kaleido Biosciences is -1.8 undefined this year.

What was the ROA of Kaleido Biosciences compared to the previous year?

The ROA of Kaleido Biosciences has increased by 0% compared to the previous year.

What consequences do high ROA have for investors of Kaleido Biosciences?

A high ROA is advantageous for investors of Kaleido Biosciences, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Kaleido Biosciences?

A low ROA can be unfavorable for investors of Kaleido Biosciences as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Kaleido Biosciences affect the company?

An increase in ROA of Kaleido Biosciences can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Kaleido Biosciences impact the company?

A reduction in the ROA of Kaleido Biosciences can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Kaleido Biosciences?

Some factors that can influence the ROA of Kaleido Biosciences include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Kaleido Biosciences important for investors?

The ROA of Kaleido Biosciences is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Kaleido Biosciences take to improve ROA?

To improve ROA, Kaleido Biosciences can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Kaleido Biosciences pay?

Over the past 12 months, Kaleido Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kaleido Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Kaleido Biosciences?

The current dividend yield of Kaleido Biosciences is .

When does Kaleido Biosciences pay dividends?

Kaleido Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kaleido Biosciences?

Kaleido Biosciences paid dividends every year for the past 0 years.

What is the dividend of Kaleido Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kaleido Biosciences located?

Kaleido Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kaleido Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kaleido Biosciences from 6/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/26/2024.

When did Kaleido Biosciences pay the last dividend?

The last dividend was paid out on 6/26/2024.

What was the dividend of Kaleido Biosciences in the year 2023?

In the year 2023, Kaleido Biosciences distributed 0 USD as dividends.

In which currency does Kaleido Biosciences pay out the dividend?

The dividends of Kaleido Biosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Kaleido Biosciences

Our stock analysis for Kaleido Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kaleido Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.